Federal regulators and courts are intensifying scrutiny of mass tort trusts over a fundamental problem: the compensation tradeoffs between claimants who filed early and those who come later, between those severely injured and those less affected, and between people suffering today versus those whose injuries haven’t yet manifested. The Department of Justice is filing amicus briefs in major bankruptcy cases, Congress is proposing six separate reform bills, and courts are blocking settlements for the first time on fairness grounds. In March 2025, a federal judge rejected Johnson & Johnson’s $9 billion talc settlement specifically because voting procedures violated claimants’ rights—a decision that signals a broader judicial willingness to police settlements that promise money but fail to deliver equitable distribution. The scrutiny reflects a hard reality: across the 60-plus active bankruptcy trusts holding over $30 billion in assets, claimants receive a fraction of what their claims are “worth.” Asbestos trusts pay a median of 25 percent of scheduled claim value. Opioid trusts average 25 percent recovery.
Talc trusts pay 8 to 15 percent. The structural reason is simple: trustees must make settlements last decades by reducing payment percentages as claims accumulate, meaning claimants who file late face far smaller payouts than those who filed early, regardless of injury severity. The tradeoff is baked into the system, and regulators now see this as a problem that requires intervention. What began as a practical settlement mechanism—allowing companies to escape bankruptcy through structured trusts that pay claimants systematically—has created a second-tier compensation regime where most injured people never receive adequate recovery. That discrepancy is what regulators, legislators, and courts are attempting to address.
Table of Contents
- What Regulatory Scrutiny Are Mass Tort Trusts Facing?
- The Claimant Fairness Crisis—How Compensation Disparities Create Two-Tier Victims
- When Present Claimants Conflict with Future Claimants—The Core Tradeoff
- Voting Fraud and Procedural Barriers to Settlement Justice
- How Bankruptcy Courts Are Restricting Nonconsensual Releases
- Congressional Efforts to Reform Trust Governance
- Trust Administration Issues and Transparency Gaps—The Fraud Problem
What Regulatory Scrutiny Are Mass Tort Trusts Facing?
The Department of Justice and federal bankruptcy courts have identified systematic compliance failures in how mass tort trusts manage claims. Trust Distribution Procedures—the rules trustees use to evaluate and pay claims—frequently fail to disclose how claimants are valued, discriminate between groups of injured people, and allow trustees to exceed their authorized compensation. Between 2024 and 2026, the DOJ filed amicus briefs in at least five major mass tort bankruptcy cases challenging trustee methodologies, signaling a shift from passive oversight to active intervention. The numbers are stark. Among 2,000-plus pending mass tort Chapter 11 cases in the federal system, the median claimant receives between 10 and 40 percent of their claim’s stated value. In the Purdue Pharma bankruptcy, which settled opioid claims through a trust, claimants recover approximately 25 percent on average.
Asbestos trusts operate across a spectrum from 1.1 percent payout (some specialized trusts) to 100 percent (well-funded trusts), but the median remains 25 percent. The Federal Judicial Conference has noted alarm at how bankruptcy courts lack standardized tools to measure whether trusts actually serve claimants equitably. One consequence: 60 to 75 percent of claimants across all mass tort trust systems receive either partial or zero recovery. The exception proves the rule. The 3M PFOA (water contamination) settlement trust, finalized in 2024, is projected to pay 70 to 80 percent of claims through 2026—rates dramatically higher than asbestos, talc, or opioid trusts. Regulators point to 3M as evidence that better-funded settlements and transparent claim processes can deliver equitable payouts, raising the question of why other trusts cannot meet the same standard.
The Claimant Fairness Crisis—How Compensation Disparities Create Two-Tier Victims
A claimant filing an asbestos claim early might receive $500,000 for a mesothelioma diagnosis valued at $2 million, earning 25 percent recovery. The same diagnosis filed five years later might yield $50,000—a 90 percent reduction due to trust depletion. This disparity has no relationship to injury severity; it reflects only filing order. Courts call this the “pennies on the dollar” problem, and it now drives regulatory scrutiny. Specific cases illustrate the magnitude. The Philips CPAP settlement, finalized in April 2024, allocated $1.1 billion to compensate over 58,000 claimants for respiratory diseases and cancer caused by defective sleep apnea devices.
The trust directed 97.7 percent of funds to personal injury claims while allocating just $25 million to medical monitoring. But Philips imposed a hard cutoff: January 31, 2025, for claim registration with zero extensions. Claims filed after that date were rejected regardless of merit. By June 2026, 622 cases remained disputed within the MDL 3014 litigation, suggesting that the fairness problem extended beyond the trust into the litigation itself. The underlying tension is structural. When trustees reduce payment percentages to preserve fund solvency over decades, they accomplish legitimate goals—ensuring trusts don’t collapse mid-way through settlements. But that mechanism inevitably penalizes late-filing claimants, creating a compensation caste system where timing determines outcome more than injury justifies.
When Present Claimants Conflict with Future Claimants—The Core Tradeoff
Every mass tort settlement must allocate money between people harmed today and people whose injuries won’t manifest for years or decades. Asbestos mesothelioma appears 20 to 50 years after exposure, so trusts must estimate how many future claimants will eventually file. This forward-looking allocation pits immediate, known claimants against speculative future victims who cannot negotiate on their own behalf. The fairness problem emerges from several directions. Current claimants want maximum immediate access to funds. Future claimants’ interests drain resources even though they lack court representation.
And the very act of estimating future claims introduces enormous uncertainty—no consensus methodology exists for valuing injuries that haven’t yet occurred. Courts have struggled to agree on what types of cases are “worth” in settlements. One partial resolution, the appointment of a “Future Claimants’ Representative” in asbestos Section 524(g) trusts, was supposed to protect unborn claimants’ interests. But in practice, the 75 percent super-majority voting requirement has become a veto weapon: law firm coalitions controlling sufficient votes can dictate settlement terms unilaterally, and they influence the appointment of the supposedly-independent Future Claimants’ Representative. The Fourth Circuit Court of Appeals, in two landmark 2025 decisions (Kaiser Gypsum and Bestwall), emphasized that bankruptcy courts must apply an “equitable lens” ensuring Section 524(g) trust plans work for both present and future claimants. That language acknowledges that prior settlements had failed this test. The en banc dissent in the Bestwall decision (October 30, 2025, denying rehearing 8-6) signaled ongoing judicial controversy about whether current structures protect future claimants adequately.
Voting Fraud and Procedural Barriers to Settlement Justice
The most prominent recent example of fairness failure came on March 31, 2025, when Judge Christopher Lopez of the U.S. Bankruptcy Court for the Southern District of Texas rejected J&J’s $9 billion Red River Talc settlement. The case involved 90,000 ovarian and gynecological cancer claims against the company. Lopez identified voting irregularities: some law firms cast tens of thousands of votes without obtaining client authorization, voters lacked adequate time and information, and votes were modified after submission. The settlement also included third-party releases shielding J&J, retailers, and other defendants from future talc lawsuits—even from claimants who had not consented to the deal. Rather than appeal, J&J declined to pursue the bankruptcy strategy and returned approximately $7 billion in reserves, indicating the company would defend talc claims in the litigation system. The rejection signaled that courts would enforce procedural fairness standards even at the cost of derailing major settlements. A broader pattern exists: approximately 40 percent of mass tort settlements occur outside judicial review and receive no fairness determination.
Unlike class action settlements, which face judicial scrutiny, mass tort settlements can proceed with attorney-negotiated terms and minimal oversight. When attorneys represent multiple claimants simultaneously, material conflicts of interest arise—representation of one client becomes constrained by representing others. And because “repeat player” attorneys interact repeatedly with the same judges and defense counsel, incentives for collusive outcomes accumulate. Federal judges facing mounting caseload pressure have little incentive to scrutinize settlement fairness, especially when both sides claim the deal saves time. One specific barrier affects claimants post-settlement. The Mallinckrodt opioid trust automatically denied claims submitted between June 11-30, 2024, because the filing period closed July 1, 2024. Those seeking to appeal faced indefinite payment delays until appeals resolved. The trust further restricted compensable damages: economic harms like lost wages and medical costs were deemed non-compensable; only general pain-and-suffering payments were available. That framework disadvantaged wage-earning claimants and low-income populations.
How Bankruptcy Courts Are Restricting Nonconsensual Releases
The U.S. Supreme Court’s Harrington v. Purdue Pharma decision (June 27, 2024) fundamentally limited bankruptcy courts’ power to release liability for non-debtor defendants without claimant consent. The case involved Purdue Pharma’s opioid settlement, which attempted to include releases protecting third parties—distributors, retailers, and affiliated companies—from future opioid liability claims. The Supreme Court held 5-4 that the Bankruptcy Code does NOT permit such nonconsensual releases except when specifically authorized by Congress. The Harrington decision interpreted Congress’s explicit provision for such releases in asbestos bankruptcies (11 U.S.C. Section 524(g)) as evidence that Congress did not intend broader release authority in other mass tort contexts.
Asbestos-related trusts remain in good standing. But non-asbestos mass tort bankruptcies now face heightened restrictions. The J&J Red River Talc rejection invoked Harrington directly: Judge Lopez found the plan violated Harrington by including impermissible third-party releases and rejected J&J’s argument that the plan qualified for a “full pay” exception. This doctrinal shift creates a new landscape for mass tort trusts. Companies can no longer use bankruptcy to bundle liability releases for affiliated entities alongside claimant compensation. Instead, companies settling through bankruptcy must either accept ongoing litigation risk for third parties or negotiate explicit consents from claimant groups—a more expensive, less efficient settlement mechanism. The tradeoff regulators are imposing: in exchange for bankruptcy protection, companies must accept ongoing liability uncertainty unless they can negotiate genuine claimant consent.
Congressional Efforts to Reform Trust Governance
Congress has proposed six separate bills targeting different dimensions of mass tort trust problems. The Ending Corporate Bankruptcy Abuse Act (S.4746 and H.R.9110, introduced July 23, 2024) addresses “Texas Two-Step” strategies in which solvent corporations isolate mass tort obligations in newly created subsidiaries while retaining operating assets in a parent company. The bills are sponsored by a bipartisan coalition: lead senators include Sheldon Whitehouse (D-Rhode Island) and Josh Hawley (R-Missouri), with House leads from Emilia Sykes (D-Ohio) and Lance Gooden (R-Texas). The mechanism would prevent automatic stays stopping litigation against both the subsidiary (“BadCo”) and parent (“GoodCo”), ensuring that company solvency does not shield defendants from accountability. The Nondebtor Release Prohibition Act (S.5415 and H.R.9223, introduced December 5, 2024) directly responds to Harrington and Red River Talc by categorically prohibiting nonconsensual release of non-debtor entity liability in bankruptcy. Sponsors include Senators Elizabeth Warren (D-Massachusetts), Dick Durbin (D-Illinois), and Richard Blumenthal (D-Connecticut). The bill is part of a broader December 2024 bankruptcy reform package.
The PROTECT Asbestos Victims Act (repeatedly reintroduced but not yet passed as of June 2026) would make knowingly submitting false asbestos trust claims a crime, authorize appointment of independent representatives for future claimants in bankruptcy, mandate trust reporting to the Centers for Medicare and Medicaid to prevent duplicate payments, and empower the DOJ’s U.S. Trustee Program to investigate fraud against asbestos trusts. Notably, current law prevents the U.S. Trustee from investigating asbestos trust fraud—a gap the DOJ has identified as enabling abuse. The Alan Reinstein Ban Asbestos Now Act (S.2811 and H.R.5373, introduced in 2025) would comprehensively prohibit the manufacture and distribution of commercial asbestos in the United States, complementing trust reform by addressing the root cause of ongoing asbestos liabilities. As of June 2026, no bill expanding Section 524(g) protections to non-asbestos mass torts has advanced to a vote, despite scholarly consensus supporting expansion. That gap leaves opioid, talc, pharmaceutical, and PFOA trusts operating under weaker governance standards than asbestos trusts—a structural inequity the legislation appears designed to remedy.
Trust Administration Issues and Transparency Gaps—The Fraud Problem
Empirical studies of asbestos trust claims from 2024 identify systemic over-claiming and inconsistent reporting that regulators view as indicative of coordination failures or fraud. A major finding: claimants and law firms over-name defendants, listing companies with minimal or no exposure. Between 2017 and 2021, allegations against primary defendants dropped from a baseline to just 6.2 percent of all claims, while non-exposed companies were added to claim lists. This inflation complicates claim processing and distorts compensation allocation. A second finding: people without malignant asbestos injury—the most serious category—comprise 86 percent of all trust claims, yet receive only 37 percent of all trust payments, suggesting systemic misallocation between claim types. A third issue: identical claimants and law firms submitted contradictory claim forms to different trusts, describing different exposure histories for the same individuals.
This inconsistency suggests either coordination problems across trust administrators or strategic claim manipulation—the DOJ characterized such patterns as “alarming evidence of fraud and mismanagement inside asbestos trusts.” The U.S. Trustee Program is currently barred by law from investigating asbestos trust fraud, a gap the DOJ has advocated to close. These transparency and fraud problems exist against a backdrop of enormous trust assets. As of June 2026, approximately $30 billion remains available across 60-plus active asbestos, talc, opioid, and PFOA trusts. Regulators view that capital as essential for compensating genuine victims. But without standardized reporting requirements, cross-trust fraud detection, and DOJ investigative authority, administrators cannot verify whether claims are legitimate or whether the same individual is recovering multiple times across different trusts. The Federal Judicial Conference’s estimate of 2,000-plus pending mass tort Chapter 11 cases underscores the scale of the problem: trusts will operate for decades, and without institutional controls, accountability will remain diffuse.
- —